The FDA grants Fast Track designation to nipocalimab for SLE, following positive results from the phase 2b JASMINE trial.

Johnson & Johnson has won U.S. Food and Drug Administration fast-track designation for its investigational nipocalimab drug in adults with systemic lupus erythematosus, a chronic autoimmune disease.

Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that its abstract detailing clinical results ongoing Phase 1/2 trial ...

Phase III results put obinutuzumab in line for approval ...

Objective Systemic lupus erythematosus (SLE) is associated with increased susceptibility to infections, including herpes ...

A retrospective cohort study found that beta-blocker use is associated with a decreased risk for incident HF in certain SAID populations.

Patients with RA or SLE who adhere to antimalarial therapy have a lower risk for hospital admission and fewer days of hospital stay than their nonadherent peers.

In a new study, right heart failure (RHF) hospitalizations of people with systemic lupus erythematosus (SLE) was associated with higher in-hospital mortality and non-fatal adverse outcomes. Lupus ...

The systemic lupus erythematosus (SLE) and lupus nephritis (LN) market across the seven major markets (7MM: the USA, France, ...

Type I interferons are a family of cytokines that play a critical role in the immune system, particularly in antiviral defence and immunomodulation. In systemic lupus erythematosus (SLE), an ...